Psilocybin therapy for depression: what the evidence shows
A clinician’s review of the evidence for psilocybin therapy for depression — the Johns Hopkins and NEJM trial results, how it works in the brain, who it may help, and why integration makes relief last.
Psilocybin therapy for depression combines a carefully dosed psilocybin session with structured clinical preparation and integration, delivered under psychological supervision. In several controlled trials it has produced rapid and, for some participants, substantial reductions in depressive symptoms — but it is an emerging treatment, not yet a licensed medicine in most countries, and it is not right for everyone.
This guide reviews what the current evidence does and does not show, how psilocybin appears to act on the depressed brain, who tends to be a candidate, and why the integration phase determines whether relief lasts. Throughout, the emphasis is the one that governs our clinical practice: honest interpretation of the science, held alongside genuine hope.
What the research actually shows
The most cited work comes from Johns Hopkins. In a randomised trial published in JAMA Psychiatry (Davis et al., 2021), 71% of participants showed a clinically significant response and 54% met criteria for remission from major depression four weeks after two supported psilocybin sessions — effect sizes several times larger than those seen in typical antidepressant trials.
A 2021 head-to-head study at Imperial College London, published in the New England Journal of Medicine (Carhart-Harris et al.), found psilocybin performed at least as well as the SSRI escitalopram across six weeks. And in the largest trial to date — a Phase 2b study of 233 people with treatment-resistant depression (Goodwin et al., NEJM, 2022) — a single 25mg dose produced a significant reduction in symptoms at three weeks. These are early-stage findings, and larger Phase 3 trials are ongoing.
How psilocybin appears to work on depression
Depression is associated with rigid, self-reinforcing patterns of negative thought and an overactive default mode network — the brain systems tied to rumination and the sense of a fixed self. Psilocybin temporarily disrupts these patterns while increasing neuroplasticity, the brain’s capacity to form new connections.
Researchers describe this as a window of flexibility: for a period after dosing, entrenched patterns loosen and become more open to change. That window is precisely why the psychological support around the session matters so much — the medicine opens the door, but therapy and integration are what walk you through it.
Who it may help — and who it is not for
Much of the strongest evidence involves major depressive disorder and treatment-resistant depression — people for whom conventional antidepressants have not worked. For these individuals in particular, the trial results have drawn serious clinical and scientific attention.
It is equally important to be clear about the limits. Psilocybin is not appropriate for everyone: a personal or family history of psychosis, certain cardiac conditions, and some medications are genuine contraindications. This is why no reputable program accepts a participant without thorough medical and psychological screening — a standard we treat as non-negotiable.
Why integration determines lasting relief
A reduction in symptoms during a trial is not the same as durable recovery. What the research increasingly suggests, and what our clinical experience confirms, is that outcomes hold when the experience is integrated — when insight is translated into changed patterns, relationships, and daily habits.
At Afterlight, integration is built into every program, with a dedicated six-session AfterCare track led by licensed clinicians. We consider it the decisive phase for depression specifically, because it is where a temporary lift becomes a sustainable change in how someone relates to themselves.
How Afterlight approaches depression safely
Every participant is screened by PhD-level psychologists before acceptance, prepared thoroughly, supported one-to-one throughout the dosing session, and offered structured integration afterwards. Sessions take place in a private, controlled setting in Negril, Jamaica, where psilocybin is legal.
We set honest expectations: psilocybin therapy shows real promise for depression, but it is not a guaranteed cure, and it works best as part of a supported clinical process rather than a stand-alone event. That candour is part of the care.
Common questions
Can psilocybin therapy help with treatment-resistant depression?
The largest trial to date — a Phase 2b study of 233 people with treatment-resistant depression (Goodwin et al., New England Journal of Medicine, 2022) — found that a single 25mg dose of psilocybin, given with psychological support, produced a significant reduction in symptoms at three weeks. These results are promising but early-stage, and psilocybin is not yet a licensed treatment in most countries. At Afterlight, suitability is always determined through individual clinical screening.
Is psilocybin therapy for depression approved or legal?
Psilocybin is not yet approved as a licensed medicine for depression in most countries, and Phase 3 trials are ongoing. However, psilocybin is legal in Jamaica, which is why Afterlight is able to deliver psilocybin-assisted therapy there openly, with full clinical oversight, screening, and integration support.
